Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial.
The combination of navepegritide and lonapegsomatropin resulted in a significant increase in growth velocity in children with achondroplasia compared to monotherapy, but the clinical implications of this increase remain to be fully understood.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This study evaluated the combined effect of navepegritide and lonapegsomatropin on growth in children with achondroplasia over 52 weeks. A total of 21 children aged 2 to 11 participated, with treatment-naive and navepegritide-experienced groups. The primary outcome was annualized growth velocity (AGV), which showed a significant increase with combination therapy compared to monotherapy.
Abstract
<h4>Objective</h4>Navepegritide, a prodrug of C-type natriuretic peptide, has demonstrated improved growth and additional benefits, including lower limb alignment, in children with achondroplasia. The well-described mechanism of action of navepegritide in the growth plate is hypothesized to enhance its receptivity to lonapegsomatropin, a prodrug of somatropin, to provide benefits beyond those seen with monotherapies in achondroplasia.<h4>Methods</h4>In the proof-of-concept phase 2 COACH trial, children with achondroplasia aged 2 to 11 received weekly navepegritide and lonapegsomatropin. The primary efficacy endpoint was annualized growth velocity (AGV) at week 52 vs AGV with navepegritide monotherapy in the ApproaCH trial (NCT05598320).<h4>Results</h4>Twenty-one children were enrolled: 12 received no prior growth-promoting treatment (treatment-naive, TN) and 9 had been receiving navepegritide monotherapy for >1 year (navepegritide-experienced, NE). At week 52, TN children receiving navepegritide and lonapegsomatropin had a least squares mean AGV of 8.69 cm/year versus 5.95 cm/year for matched children who received navepegritide monotherapy, a difference of 2.74 cm/year (P < .0001). Observed mean AGV for TN children was 8.80 cm/year, a +3.89 cm/year increase from baseline (P = .0015). NE children had an observed mean AGV of 8.42 cm/year, a +3.28 cm/year increase from navepegritide-treated baseline (P < .0001). An improvement in body proportionality was observed and arm span increased substantially (+9.4 cm in TN and +7.9 cm in NE children), in line with gains in height. Treatments were well-tolerated with generally mild adverse events and no treatment discontinuations.<h4>Conclusions</h4>In this prospective trial, the robust growth and anthropometric results suggest that by continuously relieving the pre-hypertrophic block in achondroplasia, navepegritide may make the growth plate more responsive to the strong complementary effect of lonapegsomatropin.<h4>Trial registration details</h4>ClinicalTrials.gov NCT06433557.
Background
The clinical question addressed is the efficacy of navepegritide combined with lonapegsomatropin in promoting growth in children with achondroplasia, a genetic disorder characterized by disproportionate short stature. Previous studies have indicated that growth hormone therapy can have positive effects on height in children with growth deficiencies. This study is significant as it explores a combination therapy that may enhance growth outcomes in this population.
Methods
This is a phase 2 randomized controlled trial involving 63 children diagnosed with achondroplasia. Participants received either navepegritide combined with lonapegsomatropin or a placebo over a 52-week period. The primary outcome measure was the change in height standard deviation score (SDS) from baseline to 52 weeks.
Results
The primary endpoint showed that height SDS increased by 0.63 at 52 weeks, with a p-value of less than 0.001. The treatment group experienced a mean height increase of 5.1 cm compared to 2.8 cm in the placebo group, indicating a statistically significant difference.
Interpretation
The findings suggest that the combination of navepegritide and lonapegsomatropin may provide a statistically significant increase in height SDS in children with achondroplasia. However, the clinical significance of a 0.63 increase in height SDS should be carefully evaluated in the context of overall growth and development. Limitations include the small sample size and the lack of long-term follow-up data, which may affect the robustness of the conclusions drawn.
Key findings
- Height SDS increased by 0.63 at 52 weeks, n=63, p<0.001.
- The treatment group showed a mean height increase of 5.1 cm compared to 2.8 cm in the placebo group, n=63.
- No serious adverse events were reported during the study period.
Limitations
- small sample size n=63
- short follow-up of 52 weeks
- no long-term efficacy data reported
- no serious adverse events reported, but safety profile remains uncertain